Back to Awarded Treatment Trials
Awarded Trial: 00-162
75 or 150 mg
Secondary Drug Intervention
Duration of Study Period for Each Subject
RBANS, P50 auditory evoked potential inhibition
Significant neurocognitive improvement was found on the Repeatable Battery for the Assessment of Neuropsychological Status total scale score, particularly for the lower DMXB-A dose compared with placebo. Effects were greater than those of nicotine in a similar study. Significant improvement in P50 inhibition also occurred. Patients generally tolerated the drug well.
Olincy, A. et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry. 2006 Jun;63(6):630-8.
Department of Psychiatry
University of Colorado Health Sciences Center
Box C-268-71, 4200 E. Ninth Avenue
City or Town
State or Province
Zip or Postal Code